MARKET

SRRK

SRRK

Scholar Rock Holding
NASDAQ
57.80
-1.46
-2.46%
After Hours: 57.80 0 0.00% 19:30 08/28 EDT
OPEN
58.75
PREV CLOSE
59.26
HIGH
59.30
LOW
57.17
VOLUME
809.72K
TURNOVER
--
52 WEEK HIGH
61.76
52 WEEK LOW
27.07
MARKET CAP
7.04B
P/E (TTM)
-17.4998
1D
5D
1M
3M
1Y
5Y
1D
Biotech Stocks Facing FDA Decision In September 2026
NASDAQ · 2d ago
Weekly Report: what happened at SRRK last week (0817-0821)?
Weekly Report · 4d ago
Scholar Rock (SRRK) Is Up 8.5% After De-Risking Apitegromab’s Global Filing Pathway - Has The Bull Case Changed?
Simply Wall St · 4d ago
Scholar Rock (SRRK) Stock Trades At A Premium As Its 8x Run Continues
Simply Wall St · 6d ago
Scholar Rock price target raised to $64 from $58 at Wedbush
TipRanks · 08/21 15:40
Scholar Rock Removes Catalent Indiana As Commercial Fill-Finish Facility From Its Apitegromab BLA For The Treatment Of Spinal Muscular Atrophy Under Guidance From The FDA; Now On Track To Submit Apitegromab Japanese New Drug Application By End-2026
Benzinga · 08/21 13:11
Scholar Rock removes Catalent Indiana from apitegromab BLA under FDA guidance
TipRanks · 08/21 13:10
Scholar Rock Provides Update on Global Apitegromab Regulatory Progress Across U.S., Europe, and Japan
Barchart · 08/21 08:06
More
About SRRK
Scholar Rock Holding Corporation is a biopharmaceutical company. The Company focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe and debilitating neuromuscular diseases. Its pipeline product candidates include apitegromab, a subcutaneous formulation of apitegromab, and SRK-439. The Apitegromab is an investigational fully human, intravenously administered monoclonal antibody designed to inhibit myostatin activation by selectively binding the pro- and latent forms of myostatin in the skeletal muscle. The SRK-439, is an investigational, subcutaneously administered fully human anti-pro/latent myostatin antibody that has high inhibitory potency while maintaining selectivity towards myostatin. Its early-stage pipeline includes additional programs for the treatment of patients with rare, severe, and debilitating neuromuscular diseases.

Webull offers Scholar Rock Holding Corp stock information, including NASDAQ: SRRK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SRRK stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SRRK stock methods without spending real money on the virtual paper trading platform.